Case Report

Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma

Tsukasa Narukawa Fumiya Hongo Atsuko Fujihara Akihisa Ueno Toru Matsugasumi Osamu Ukimura
Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan

Keywords
Nivolumab · Renal cell carcinoma · Tyrosine kinase inhibitor · Tumor lysis syndrome

Abstract
Nivolumab, a programmed death-1 checkpoint inhibitor, is worldwide available for metastatic renal cell carcinoma (mRCC). Limited data exist on the response to vascular endothelial growth factor receptor-tyrosine kinase inhibitor (TKI) therapy after administration of nivolumab. In this case study, we report on a patient with tumor lysis syndrome (TLS), which was induced by pazopanib after the administration of nivolumab. A 69-year-old woman with a primary diagnosis of mRCC received pazopanib as a fourth-line therapy, after sunitinib, axitinib, and nivolumab as first-, second-, and third-line therapies, respectively. Two weeks after the administration of pazopanib, she presented to the emergency room of our institution, complaining of fatigue associated with nausea and diarrhea. Her laboratory results showed hyperphosphatemia, hyperuricemia, hypocalcemia, and possible acute kidney injury; the results were consistent with TLS. Our case report highlights TLS as a potential reaction to pazopanib following nivolumab; and we consider careful observation is necessary when administering TKI after immune checkpoint inhibitors.

Introduction
Clear-cell renal cell carcinoma (ccRCC) is associated with mutations in the VHL gene, and therefore, vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI) have been developed as anticancer therapies in ccRCC [1]. From 2006 to 2017, the standard first-line therapies of metastatic ccRCC (mccRCC) were VEGF-targeted therapies [2]. In contrast, nivolumab, a programmed death-1 (PD-1) checkpoint inhibitor, was the first...
immune checkpoint inhibitor (ICI) to be approved for advanced RCC in Japan, showing an overall survival superior to everolimus [3]. In addition, the combination of nivolumab and ipilimumab is the standard first-line treatment for patients with international metastatic data-base consortium (IMDC) intermediate- or poor-risk disease, based on the clinical trial of checkmate 214 [4]. Since 2017, VEGFR-TKIs, mammalian target of rapamycin (mTOR) inhibitors, and nivolumab have been frequently used as second- and subsequent-line therapies in Japan [5]. Previous reports revealed the durable response to ICIs [6], which may suggest that the influence of ICIs remains after interrupting their use. Therefore, VEGF-targeted therapies after ICIs may achieve a mutual effect or may result in completely unexpected adverse events (AEs). In this case study, we report a case of tumor lysis syndrome (TLS), which was induced by the administration of pazopanib after nivolumab.

Case Report

A 66-year-old woman with suspected crown tumor went to the local hospital. A biopsy of the cranial bone tumor revealed clear-cell carcinoma. Computed tomography (CT) showed a right renal tumor with multiple lung and bone metastases. The patient was diagnosed with metastatic right renal cell carcinoma (cT1bN0M1) and came to our hospital for treatment. First, she underwent laparoscopic right renal resection. Then, she was categorized as IMDC intermediate risk and received sunitinib for an initial 7 months, axitinib for the next 6 months as second-line therapy, and nivolumab for the following 6 months as third-line therapy. In spite of these treatments, CT revealed that the cranial bone tumors had increased in size, infiltrating the surrounding tissue as an extra bone mass (Fig. 1), and a new liver lesion had appeared. After that, she was admitted to our hospital to start pazopanib as fourth-line therapy in February 2019. At this point, she was categorized as IMDC intermediate risk, and her serum uric acid level was normal with 5.4 mg/dL.

During hospitalization, she received 800 mg pazopanib daily without any AEs and was discharged on Day 10 after administration of pazopanib. Two days after discharge from the hospital, she presented to the emergency room with complaints of CTCAE v4.0 grade 2 fatigue.

Fig. 1. CT scan showing a cranial bone tumor which has infiltrated the surrounding tissue as an extra bone mass (arrows).
associated with CTCAE v4.0 grade 2 nausea and grade 1 diarrhea. Physical examination showed a temperature of 40.5°C, a blood pressure of 132/48 mm Hg, and a heart rate of 120 beats per minute. She denied any abdominal pain during palpation. Her chest and abdomen CT showed that the lung metastasis had decreased (Fig. 2). The laboratory results are shown in Table 1.

**Table 1.** Laboratory values on Days 8, 12 (day of ER admission), and 13 (day of ICU admission) after the initiation of pazopanib therapy

| Parameter          | Reference range | Day 8 | Day 12 | Day 13 |
|--------------------|-----------------|-------|--------|--------|
| WBC, /µL           | 3,300–8,600     | 4,400 | 6,200  | 3,300  |
| RBC, ×10⁴/µL       | 386–492         | 459   | 441    | 474    |
| Hb, g/dL           | 11.6–14.8       | 13.3  | 12.9   | 13.5   |
| Platelets, ×10⁴/µL | 15.8–34.8       | 26.9  | 3.6    | 3.0    |
| PT, %              | 73–140          | –     | 65     | 52     |
| PT-INR             | 0.87–1.12       | –     | 1.20   | 1.35   |
| FDP, /µg/mL        | 0–5             | –     | 41.6   | 54.9   |
| AST, U/L           | 13–30           | 17    | 277    | 339    |
| ALT, U/L           | 7–23            | 10    | 66     | 83     |
| LDH, U/L           | 124–222         | 247   | 1,380  | 1,762  |
| ALB, g/dL          | 4.1–5.1         | 3.8   | 3.4    | 2.4    |
| BUN, mg/dL         | 8.0–20.0        | 19.5  | 57.5   | 64.7   |
| Cr, mg/dL          | 0.46–0.79       | 0.80  | 2.30   | 2.95   |
| UA, mg/dL          | 2.6–5.5         | –     | –      | 10.1   |
| CRP, mg/dL         | 0–0.14          | 0.60  | 19.56  | 22.21  |
| Na, mEq/L          | 138–145         | 139   | 131    | 131    |
| K, mEq/L           | 3.6–4.8         | 4.5   | 4.0    | 4.4    |
| Ca, mg/dL          | 8.8–10.1        | 9.2   | 8.5    | 7.0    |
| P, mg/dL           | 2.7–4.6         | 3.3   | –      | 5.9    |

ALB, albumin; ALT, alanine phosphatase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; Ca, calcium; Cr, creatinine; CRP, C-reactive protein; ER, emergency room; FDP, fibrinogen/fibrin degradation product; Hb, hemoglobin; ICU, intensive care unit; INR, international normalized ratio; K, potassium; LDH, lactate dehydrogenase; Na, sodium; P, phosphorus; PT, prothrombin time; RBC, red blood cell count; UA, uric acid; WBC, white blood cell count.
In the emergency room, a CTCAE grade 2 acute kidney injury was discovered, and disseminated intravascular coagulation was diagnosed according to the Japanese Association of Acute Medicine (JAAM) criteria [7]. At that point, she discontinued pazopanib and was treated with hydration at 200 mL/h, thrombomodulin alpha, and broad-spectrum antibiotics meropenem, which was started empirically due to the possibility of sepsis in the setting of immunocompromised state. Within 24 h, her laboratory values showed hyperphosphatemia (5.9 mmol/L), hyperuricemia (10.1 mg/dL), and hypocalcemia (7.0 mg/dL), and acute renal failure got worse (creatinine: 2.3–2.95 mg/dL), which were all consistent findings with laboratory TLS (according to the Cairo and Bishop classification) [8]. The laboratory results are also shown in Table 1. Then, she was admitted to the intensive care unit for the management of TLS. Despite intensive medical care, including renal replacement therapy, her renal function did not recover. Due to her poor prognosis, the attending physicians consulted her family, and they decided not to do further life-prolonging therapy. Eventually, our patient died under palliative care the next day following intensive care unit admission.

**Discussion**

TLS is an oncologic emergency, characterized by the extensive destruction of tumor cells, which results in the release of intracellular content, including uric acid, potassium, phosphorus, and calcium. Hyperuricemia, hyperphosphatemia, hyperkalemia, and hypocalcemia occur in the process and can lead to acute kidney injury, cardiac arrhythmias, seizures, or death [8]. In our case, a serum lactate dehydrogenase concentration of 1,380 U/L and decrease of the lung lesion may reveal cell lysis, which is consistent with TLS. TLS is most commonly seen during the treatment of hematological malignancies, such as Burkitt lymphoma or acute leukemia [8]; however, there has been an increase of TLS reports in RCC recently [9–11].

**Table 2. Summary of reported cases treated with TKIs as second-line therapy after ICIs**

| 1L ICI | N (%) | 2L TKI | N (%) | mPFS, months | mOS, months | Toxicity, n (%) |
|--------|-------|--------|-------|--------------|-------------|-----------------|
| Auvry et al. [14] (n = 33) PD-1+CTLA-4 blockade (followed by maintenance anti-PD-1) | 33 (100) | All | 8 | 14 (42) |
| | | Sunitinib | 17 (52) | 8 | 11 |
| | | Pazopanib | 6 (18) | | |
| | | Axitinib | 8 (24) | 7 | NR |
| | | Cabozantinib | 2 (6) | | |
| | | Other | 5 | | |
| Shah et al [15] (n = 70) Anti-PD-(L)1 single agent | 12 (17) | All | 13.2 | 12 (17) |
| | PD-1+CTLA-4 blockade (followed by maintenance anti-PD-1) | 33 (47) | Sunitinib | 6 (9) | 1 (17) |
| | PD-(L)1+ anti-VEGF therapy | 25 (36) | Pazopanib | 19 (27) | 8 (42) |
| | | Axitinib | 25 (36) | 3 (12) |
| | | Cabozantinib | 20 (28) | 0 (0) |

1L, first line; 2L, second line; CTLA-4, cytotoxic T lymphocyte-associated protein 4; ICI, immune checkpoint inhibitors; mOS, median overall survival; mPFS, median progression-free survival; PD-1, programmed death-1; PD-L1, programmed death ligand-1; VEGF, vascular endothelial growth factor TKI, tyrosine kinase inhibitor.
Pazopanib is a VEGFR-TKI which has been approved for first-line treatment of patients with IMDC low-risk disease in Japan [5], and pazopanib-related TLS in mRCC has previously been reported [11]. Pazopanib is almost completely (>99.9%) bound to serum albumin, and a low serum albumin level may lead to a higher free fraction of pazopanib, and this may result in a higher toxicity of pazopanib. In our case, serum albumin level was decreasing gradually, and it may be one factor for TLS progression. TLS induced by other TKI, such as sunitinib, has previously been described in patients with RCC [9, 10]. However, in these reported cases, TKI was used as first-line treatment, and it has never been described in a patient with RCC and a history of TKI use, treated with other TKIs.

Recently, the JAVELIN Renal 101 Phase 3 trial has been published, a TKI/ICI registration trial, and has demonstrated superior progression-free survival (PFS) for the combination of axitinib and avelumab over sunitinib (13.8 vs. 8.4 months, HR 0.69) [12]. Furthermore, the KEYNOTE-426 trial has demonstrated both PFS and overall survival advantage of axitinib plus pembrolizumab over sunitinib (median PFS 15.1 vs. 11.1 month, HR 0.69) [13]. These trials indicate that the combination of TKI and ICI may have more impact on cancer than TKI monotherapy.

In contrast, a durable response to ICI has previously been reported [6], and in our case, the combination of pazopanib and the prolonged effect of nivolumab may have cause TLS, similar to TKI/ICI combination therapy. Previous reports on second-line TKI after ICI are summarized in Table 2 [14, 15]. Each treatment has a certain level of therapeutic effect and AEs. Shah et al. [15] reported that 8 of 19 (42%) patients treated with pazopanib after ICI discontinued treatment due to its toxicity, and the most frequent reason (5 of 8, 63%) was transaminitis. The discontinuation rate of pazopanib was higher than that of other TKIs (13% for axitinib, 17% for sunitinib, 0% for cabozantinib). Although the numbers are not large, they may reveal that a type of TKI is not suitable for sequential treatment after ICI. In any case, we considered close follow-up is necessary when administering TKI after ICI.

**Conclusion**

To the best of our knowledge, this is the first report of TLS induced by pazopanib after nivolumab; it suggests the need of careful observation when administering TKI after ICI.

**Statement of Ethics**

Our patient provided written informed consent for the publication of her clinical course.

**Disclosure Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Contributions

Tsukasa Narukawa designed the study and wrote the initial draft of the manuscript. Fumiya Hongo and Osamu Ukimura contributed to revise it critically for important intellectual content. All other authors have contributed to data collection and interpretation and reviewed the manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References

1. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017 Jan;376(4):354–66.
2. Barata PC, Rini BL. Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin. 2017 Nov;67(6):507–24.
3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov;373(19):1803–13.
4. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 Apr;378(14):1277–90.
5. Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, et al. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist. 2017 Jun;22(6):667–79.
6. McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015 Jun;33(18):2013–20.
7. Gando S, Saitoh D, Ogura H, Fujishima S, Mayumi T, Araki T, et al. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care. 2013 Jun;17(3):R111.
8. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004 Oct;127(1):3–11.
9. Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet. 2007 Jun;369(9577):1923–4.
10. Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs. 2010 Oct;28(5):690–3.
11. van Kalveeven MW, Walraven M, Hendriks MP. Pazopanib-related tumor lysis syndrome in metastatic clear-cell renal cell carcinoma: a case report. Invest New Drugs. 2018 Jun;36(3):513–6.
12. Motzer RJ, Pekov K, Haenen J, Rini B, Albonesi L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar;380(12):1103–15.
13. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar;380(12):1116–27.
14. Aufray M, Aucin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, et al. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer. 2019 Feb;108:33–40.
15. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019 Jun;114:67–75.